1. Home
  2. |Insights
  3. |Calling All Innovators: DIUx Announces Strategic Outreach Plan

Calling All Innovators: DIUx Announces Strategic Outreach Plan

Client Alert | less than 1 min read | 12.06.16

On November 30, DIUx participated in a panel hosted by the Center for a New American Security and further described its efforts to shift the acquisition innovation culture from a sole-buyer market headed by DoD into an arena in which nontraditional suppliers can work collectively with military workforce who have insight on the technological vulnerabilities the military currently faces. DIUx announced its intention to host workshops and presentations for nontraditional suppliers who otherwise would be discouraged or intimidated by contracting with the DoD, to work to shorten and/or modify traditional DoD procurement requirements, and to endorse flexible arrangements with nontraditional suppliers.

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights